Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 10 - 13 tags : Europe save search
Hyzon Motors' Europe manufacturing facility capable of producing 825 hydrogen-powered fuel cell electric vehicles per year
Published: 2021-10-13 (Crawled : 21:00) - prnewswire.com
HYZN | $0.592 -3.74% -3.89% 280K
|
|
| O: 4.94%
H: 2.16%
C: -7.36%
fuel cell europe hydrogen electric vehicles electric vehicle vehicles
CNH Industrial announces temporary plant shutdowns in Europe
Published: 2021-10-13 (Crawled : 21:00) - globenewswire.com
CNHI | $12.31 -0.73% 0.0% 6.9M
|
Producer Manufacturing
|
| O: 0.12%
H: 2.17%
C: 2.1%
europe trial
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology
Published: 2021-10-13 (Crawled : 14:15) - biospace.com/
NTLA | $21.57 1.17% 1.16% 1.4M
|
Health Technology
|
| O: -0.68%
H: 2.19%
C: -1.46%
crispr ocular collaboration technology therapy
New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
Published: 2021-10-13 (Crawled : 13:15) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.27%
H: 2.38%
C: 1.07%
t-cell
Evelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Published: 2021-10-13 (Crawled : 12:15) - biospace.com/
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 0.88%
H: 0.0%
C: -10.11%
multiple sclerosis treatment europe sclerosis research preclinical pre-clinical
Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress
Published: 2021-10-13 (Crawled : 12:00) - biospace.com/
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: 3.43%
H: 3.79%
C: 1.9%
europe therapy
Relief Reports that its U.S. Collaboration Partner has Announced Progress on Worldwide Commercial Scale Development of ZYESAMI(TM) (aviptadil)
Published: 2021-10-13 (Crawled : 09:00) - biospace.com/
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 43.85%
H: 2.99%
C: -2.78%
collaboration aviptadil commercialization
BIO-Europe
Published: 2021-10-13 (Crawled : 03:00) - immunoprecise.com
IPA | $1.24 0.0% 150K
|
Professional, Scientific, and T...
|
| O: 0.33%
H: 4.23%
C: 3.91%
europe
13th Annual PEGS Europe
Published: 2021-10-13 (Crawled : 03:00) - immunoprecise.com
IPA | $1.24 0.0% 150K
|
Professional, Scientific, and T...
|
| O: 0.33%
H: 4.23%
C: 3.91%
europe
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.